# ALS Reversals - Lunasin Regimen

> **NCT02709330** · PHASE2 · COMPLETED · sponsor: **Richard Bedlack, M.D., Ph.D.** · enrollment: 60 (actual)

## Conditions studied

- ALS (Amyotrophic Lateral Sclerosis)

## Interventions

- **DRUG:** Lunasin Regimen
- **OTHER:** Historical control

## Key facts

- **NCT ID:** NCT02709330
- **Lead sponsor:** Richard Bedlack, M.D., Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-09-13
- **Final completion:** 2017-09-13
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709330, "ALS Reversals - Lunasin Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02709330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*